
|Videos|November 15, 2020
AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
Author(s)OTE Staff Reports
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Lumvoa gains US FDA approval for thyroid eye disease with class-first broad label
2
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
3
DEX implant shows benefit across RVO subgroups in real-world retrospective study
4
Q&A: Uveitis risk rises as immune checkpoint inhibitor use expands
5

























